Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation powder for oral inhalation use. It provides bronchodilation for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adults. GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a LABA that acts on the bronchial smooth‑muscle pathway to improve airflow in chronic respiratory diseases.

- Asthma: helps maintain open airways and reduces symptoms when used regularly with an inhaled corticosteroid. - Chronic obstructive pulmonary disease (COPD): provides long‑acting bronchodilation to improve exercise tolerance and reduce breathlessness. - Exercise‑induced bronchoconstriction: used before physical activity to prevent narrowing of the airways.

Formoterol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Tremor: mild shaking of the hands. - Headache: occasional tension‑type headache. - Throat irritation: mild soreness or dryness in the throat. - Cough: transient cough after inhalation. - Palpitations: sensation of a rapid or irregular heartbeat. - Nasal congestion: mild blockage of the nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Hypokalemia: low blood potassium levels detectable on laboratory testing. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose, particularly in diabetic patients. - Pulmonary hypertension: increased pressure in the lung arteries, reported rarely.

When using Oxis Turbohaler, patients and healthcare providers should consider several safety measures.

- Assess asthma control: ensure the patient is on an appropriate inhaled corticosteroid regimen before adding a LABA. - Monitor cardiovascular status: watch for tachycardia, palpitations, or hypertension, especially in patients with heart disease. - Evaluate for paradoxical bronchospasm: discontinue if breathing worsens after inhalation. - Use with a spacer if needed: patients who have difficulty coordinating inhalation may benefit from a spacer device. - Review concomitant medications: check for other β‑agonists to avoid excess β2 stimulation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Formoterol can interact with several drug classes, requiring attention to avoid reduced efficacy or increased adverse effects.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): can potentiate cardiovascular effects such as tachycardia.

Moderate Interactions (Monitor Closely): - Other β2‑agonists: additive stimulation of β2 receptors may increase risk of tachycardia. - Diuretics (especially loop diuretics): may exacerbate hypokalemia when combined with LABA therapy. - Theophylline: concurrent use may increase the risk of cardiac side effects. - Anticholinergic bronchodilators: combined therapy may enhance bronchodilation but requires monitoring for cough. - Certain antihistamines: may cause additive central nervous system effects such as tremor.